Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News on Pharma

Reckitt Benckiser’s shares slump after Abbott baby formula ruling over bowel disease link

British group says claims products cause serious bowel condition NEC are ‘not supported by science’

The Guardian - UK

NewAmsterdam Touts Cholesterol Drug Success, But Results Trail Analysts' Expectations

NewAmsterdam said Monday its experimental drug lowered "bad" LDL cholesterol But the results were below biotech stock analysts' views.

Investors Business Daily

Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug

Biogen stock tumbled Friday after European regulators rejected its Eisai-partnered Alzheimer's treatment, citing steep side effects.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

'Grinding halt': shortage could cause hospital chaos

Australia's health system could come to a "grinding halt" within days if a shortage of intravenous fluid isn't addressed, a leading doctor has warned.

AAP

Medical Giant Danaher Nears Breakout On This 'Stark Contrast' With A Key Rival

Danaher stock flirted with a breakout Tuesday on the back of its unexpectedly strong sales from its molecular testing services.

Investors Business Daily

Bosses Resign At Japan Health Supplement Firm Probing Deaths

The chairman and president of a major Japanese dietary supplement maker announced their resignation on Tuesday, as the company probes dozens of deaths potentially linked to products meant to lower cholesterol.

International Business Times

The 'Shocking' And 'Alarming' Report That Sent IBD 50's Medpace Into A Nosedive

Medpace stock crumbled late Tuesday on a "shocking bookings miss" and after slashing its 2024 sales guidance by $25 million at the midpoint.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Dear Pharmac – do things differently: what David Seymour’s expectations could mean for the drug-buying agency

Associate Health Minister David Seymour’s recent letter of expectations to drug buying agency Pharmac could fundamentally change the way the organisation makes decisions. Some of these changes could also make Pharmac’s job harder and its decisions more unpopular.

The Conversation

Ozempic knockoffs flood US market thanks to ‘blind spot’ in FDA rules

Pharmacy alliance president counters that ‘it’s an intentional policy’ so patients don’t go without medication

The Guardian - US

Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong

Ionis Pharmaceuticals stock surged Monday after the company unveiled promising results for a drug that treats a rare genetic condition.

Investors Business Daily

Iqvia Bolts Higher After A Surprise Segment Beat Saved Its Second Quarter

Iqvia stock bolted higher Monday after the contract research firm raised its outlook for the year on the back of unexpected strength.

Investors Business Daily

UN Urges Gilead To 'Make History' With Game-changing HIV Drug

Gilead could bring the AIDS pandemic towards an end if the US pharmaceutical giant opens up access to its game-changing new HIV drug, the head of UNAIDS told AFP. Winnie Byanyima urged Gilead to "make history" by allowing generic manufacturing of Lenacapavir, a twice-yearly injectable antiretroviral medication used to treat…

International Business Times

3 Healthcare Stocks With High Profit Margins

With an aging population, increasing drug demand, and the development of advanced technologies, the healthcare industry is booming. Thus, it could be wise to invest in fundamentally sound healthcare stocks, Veeva Systems (VEEV), Align Technology (ALGN), and Medpace Holdings (MEDP), which have high-profit margins. Read on.

StockNews.com

3 Pharmaceutical Stocks With Strong Pipelines

The pharmaceutical industry is flourishing due to increasing medical demands and rising healthcare spending worldwide. Hence, pharma stocks Eli Lilly (LLY), Johnson & Johnson (JNJ), and Merck & Co. (MRK), with strong pipelines, might be worth buying. Read more….

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Three Surprising Names That Could Be On Biogen's Buyout Shortlist

Biogen stock has mostly trended sideways this year, but that could soon change with up to $10 billion in dry powder, an analyst said Tuesday.

Caixin Global

Shanghai Composite Index Ended Nearly Flat on Friday

Shenzhen Component Index closed down 0.18%

Investors Business Daily

Cytokinetics' Wild Ride: CEO Defends Deal That Rattled Wall Street

Cytokinetics stock plummeted on a Royalty Pharma deal for three of its heart disease drugs. Here's what CEO Robert Blum says investors missed.

The Street

Pfizer stock leaps on obesity drug challenge to Ozempic, Zepbound

Pfizer is looking to challenge leaders Eli Lilly and Novo Nordisk in the fast-growing market for weight loss drugs.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Lantheus Stock Gets A Radioactive Surge On Medicare Proposal

Lantheus stock rocketed to a record high Wednesday after a Medicare proposal suggested hiking the reimbursement rate for some diagnostics.

The Street

Analysts revamp Eli Lilly stock price target ahead of Q2 earnings

Eli Lilly, with a market value of nearly $900 billion, has vaulted past Tesla into the top 10 list of U.S. companies.

The Independent UK

The threat of litigation looms as Purdue Pharma returns to settlement talks

OxyContin maker Purdue Pharma, the family that owns it and lawyers for thousands of parties with claims against it are getting ready to work on a new settlement after the U.S. Supreme Court rejected the last one

The Independent UK

South Africa drops probe of J&J after it agrees to lower price of TB drug and withdraws patent

Medical advocacy groups welcomed Johnson & Johnson’s decision not to enforce its patent on a critical tuberculosis medication, allowing its production at much lower prices, after South African authorities opened an investigation into the conglomerate

Evening Standard

London biotech secures £90 million backing

Myricx Bio’s £90 million Series A fundraising will initially focus on developing its work treating solid tumours, such as breast and gastric cancers, but potentially can apply across all cancers

Investors Business Daily

What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients

A renaissance is stirring in cholesterol treatment, and it could drive Merck, Novartis and other stocks higher, while delivering new choices for millions of patients.

Investors Business Daily

Eli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer's Drug

Eli Lilly won FDA approval for its Alzheimer's treatment, donanemab, on Tuesday. But Eli Lilly stock remained in the red.

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.